January 27: The Week in Cancer News
Many women underestimate dense breast effect on cancer risk, and FDA approves targeted therapy for colorectal cancer.
Progress Against Cancer
Many women underestimate dense breast effect on cancer risk, and FDA approves targeted therapy for colorectal cancer.
Pembrolizumab was approved to treat some patients with lung cancer after surgery and chemotherapy. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the adjuvant treatment of stage IB, II, or...
Women experience faster decline in physical function after cancer, and treatment quality for lung cancer varies across the US.
The FDA approved tucatinib for certain patients with unresectable or metastatic colorectal cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib (Tukysa) in combination with trastuzumab for the treatment...
The FDA approved zanubrutinib, a second-generation Bruton’s tyrosine kinase inhibitor. The U.S. Food and Drug Administration (FDA) has approved zanubrutinib (Brukinsa) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ...
Women over 65 are diagnosed at later stages of cervical cancer, and other stories from this week in cancer news, selected by the editors of Cancer Today.
A new immunotherapy targets six different viruses that can cause infections when the immune system is suppressed to allow potentially life-saving transplants, according to trial results published in the AACR journal Clinical Cancer Research.
Therapeutic antibodies carry ‘payloads’ to destroy cancer cells.
Neurologist David Schiff discusses the significance of new evidence-based guidance on how to treat brain metastases from solid tumors.
Cardiovascular mortality rates for survivors of early-stage Hodgkin lymphoma outpace cancer-related mortality.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More